The ability to achieve advances in the treatment of hematopoietic malignancies depends on better insight into the molecular mechanisms underlying their deregulated growth. Critical insight into this is afforded by identifying genetic lesions within these neoplasms. In mice, nononcogene-containing retroviruses can induce a variety of hematopoietic neoplasms, the genesis of which is dependent on proviral integration resulting in dysregulated expression of key growth regulatory genes. The characterization of proviral insertion sites constitutes a powerful approach to the identification of genes involved in the neoplastic process.
The pathogenesis of retrovirally-induced hematopoietic tumors in the mouse involves a complex interaction between the virus and host, the outcome of which is determined by virus type and mouse strain. The Friend murine leukemia virus is the helper virus component of the Friend complex and proviral insertional activation or inactivation of specific growth regulatory genes such as Trp53 and Fli1 leads to a clonal erythroleukemias. Certain mouse strains, such as C57BL6, are resistant to F-MuLVinduced erythroleukemia, and develop myeloid leukemias and lymphomas upon infection, with a latency nearly twice as long as for the F-MuLV-induced erythroleukemias. The sites of proviral insertion in F-MuLV-induced myeloid leukemias and lymphomas have been largely unreported but these sites are of considerable interest since they are likely to yield insight into the corresponding human diseases. In our previous work, we demonstrated that F-MuLV accelerated myelomonocytic neoplasms in transgenic mice harboring an SV40 early region transgene under the control of a myelomonocytic promoter region (gp91phox):
1 F-MuLV shortened the latency of tumorigenesis from 167 to 103 days, and this was associated with the presence of proviral insertions at Fli1, and a novel site, Fim4. Here, we further analyze the sites of proviral insertion in F-MuLV-induced nonerythroid tumors arising in C57BL/6 mice.
Nontransgenic (six mice) and gp91phox-SV40-transgenic (80 mice) C57BL/6 mice were injected as neonates with F-MuLV and aged for tumor development. Among the resulting lesions were 75 hematopoietic malignancies and 12 preleukemias. The neoplasms included histiocytic sarcomas, myeloid leukemias and lymphoid leukemia/lymphomas (Table 1) . From tumor DNA, proviral insertion sites were determined by inverse PCR followed by molecular cloning and DNA sequence analysis. A total of 762 proviral integration sites (PIS) were characterized. An examination of the compiled PIS allowed us to determine 52 common insertion sites (CIS) present in three or more tumors, when considering our data and that present in Table 1 Histopathologic diagnoses for lesions analyzed 35  Histiocytic sarcoma  20  Myelomonocytic leukemia  12  Lymphoid leukemia or lymphoma  12  Preleukemia  2  Myelodysplasia  1  Erythroleukemia  7 No tumor
Number of cases Diagnosis
Total number of diagnoses is greater than the number of lesions (75 specimens) since some lesions had more than one tumor type. Tumors were generated as described 1 . Tumors were diagnosed by histopathologic examination of H+E-stained spleen, liver, bone marrow and lymph nodes. Preleukemias were diagnosed as a moderate (two-to three-times normal weight) increase in spleen weight, with expansion of either red or white pulp areas of the spleen, but no marked infiltration into liver or evident circulating blasts on Giemsa-stained smear of peripheral blood. Also taken into consideration for the diagnosis of preleukemia was the finding of proviral insertion into common sites or into cancer-related genes. (Table 2b) , while 12 CIS represent novel sites of insertion (Table 2a ). These new insertion site genes represent excellent cancer gene candidates (Prim2, Gdi3, Scap2, Nkx2-3, and St7). Four CISs encode novel uncharacterized genes (No.'s 9-12, Table 2a ). All three Prim2 proviral insertions were in the opposite transcriptional orientation within intron 7, thus raising the possibility that the net effect could be loss of gene function, truncation of an overexpressed N-terminal portion, or overexpression of a C-terminal fragment via transcriptional initiation at a cryptic promoter downstream of the proviral insertion. Prim2, located in human at chromosome 6p12-p11.1, encodes a 58 kDa protein, which, together with the p49 subunit, forms the heterodimeric DNA primase enzyme. DNA primase plays a key role in both the initiation of DNA replication and the synthesis of Okazaki fragments for lagging strand synthesis, specifically by synthesizing short RNA molecules that prime DNA synthesis. While p49 possesses the phosphodiester bond formation activity by itself, p58 plays a critical regulatory role via protein-protein interactions, mediating complex formation with DNA polymerase a, as well as binding to the origin of replication protein, ORC2. Primase is involved in checkpoint pathway coupling DNA replication to repair. 3 It is possible that within the context of such regulatory functions p58, or a fragment thereof that is generated by the provirally activated locus, may have a dominant stimulatory effect on cell growth. This will be the focus of future studies.
Two tumors were identified with proviral insertions into intron 15 of Pecam1, encoding platelet endothelial cell adhesion molecule-1 (or PECAM1), a member of the cell adhesion molecule (CAM) subgroup of the immunoglobulin (Ig) superfamily. PECAM1 is expressed on the surface of circulating hematopoietic cells. It is also a major constituent of the endothelial cell intercellular junction. PECAM1 is implicated in several functions including transendothelial migration of leukocytes, angiogenesis, integrin activation and cell survival. In some cases of AML and ALL, leukemic cells have low levels of PECAM1 expression which may contribute to the decreased adhesiveness of leukemia cells. 4 Consistent with this, endothelial cells from Pecam1 À/À mice proliferate more rapidly than similarly transformed cells from normal mice and are less adherent and migrate more slowly. 5 Pecam1 is expressed in hematopoietic progenitor cells capable of repopulating irradiated recipients, but its role in these cells is not known. It may be that loss of Pecam1 expression confers a growth advantage on cells but not enough to induce leukemia. The human homolog is located on chromosome 17q23.
The Ray1/St7 locus harbors two different starts of transcription and several alternatively spliced exons, thus possessing the possibility of generating multiple protein isoforms including RAY1 and ST7, which bear little homology to known proteins and whose function is not known. RAY1 and ST7 are generated from two different transcription start sites and we identified three proviral insertions in the interval between the first exon of RAY1 and that of ST7. ST7 is a candidate tumor suppressor gene with proposed involvement in primary ovarian carcinomas, based on allelic loss at 7q31.1 in such carcinomas. 6 However, this conclusion is disputed by two independent studies (e.g., 7 ). Our data indicate that overexpression rather than loss of RAY1/ST7 expression contribute to malignancy. Studies to show this is actually the case will be the focus of future work. Tumor types: 1: preleukemia; 2: myeloid leukemia; 3: monocytic leukemia; 4: histiocytic sarcoma; 5: lymphocytic leukemia/lymphoma; 6: myelodysplastic syndrome; 7: erythroleukemia.
High-molecular-weight DNA was extracted from frozen spleen tumors and inverse PCR was performed as described (1) . PCR products from the secondary PCR reaction were cloned into pAMP1-cloning vector (Gibco BRL). Plasmids were sequenced using M13 forward primers by automated sequencing at the Keck Biotechnology Resource Laboratory (http://info.med.yale.edu/wmkeck/). The resultant sequences were edited and then compared against the public sequence databases (http://www.ensembl.org/Mus_musculus/ and http://www.ddbj.nig.ac.jp/E-mail/homology.html). All PIS were compared with and submitted to the Mouse Retroviral Tagged Cancer Gene Database (http://wwwgenome2.ncifcrf.gov/RTCGD). Letters to the Editor
The goal of this study was to gain further insight into the mechanisms involved in F-MuLV-induced neoplastic transformation of nonerythroid hematopoietic lineages. We have utilized the unique combination of F-MuLV and C57BL/6 in order to select for nonerythroid tumors. In addition, most of the tumors were generated in mice with myelomonocytic-specific expression of SV40 early region, which produces SV40T antigen, a multifunctional protein that can bind to and inactivate p53 and Rb. Thus, we are obviating the need for inactivation of either Rb or p53. One of the expectations in this study was to identify a small set of genes that cooperate with SV40 early region.
1 However, the results showed a large number of different insertions, with only three genes being found more than three times: Evi1 (17 times), Fim4 (four times) and Fim5 (five times). This suggests that a large number of different genes can cooperate with SV40 early region in the generation of myelomonocytic neoplasms, but it also precludes one from discerning a set of necessary or sufficient cooperating oncogenes or pathways in this model system. It is currently postulated that integration of ecotropic proviruses tends to occur at or near the 5 0 ends of transcriptionally active genes. Recent studies of proviral insertions occurring in retroviral marking studies in hematopoietic stem cells showed that proviral insertions occur in genes with known roles in growth regulation; 8 even in the absence of leukemia and using a replication defective virus. There is likely a selection process in which dominant clones harboring growth-promoting proviral insertions emerge out of the population of infected cells. In this study, 8 the retrovirus was nonreplicating, thus precluding acquisition of additional leukemogenic insertions that would complete the transformation process. That we identified 12 new CIS genes in this study probably reflects our use of a distinctive transgenic strain harboring SV40 early region under the control of the myelomonocyte-specific gp91phox promoter, which likely caused expansion of specific cells within the host hematopoietic system. Thus, the particular spectrum of insertions we obtained likely reflects the complement of genes that is transcriptionally active in the partially transformed myelomonocytic progenitors within the transgenic, preleukemic mouse. If true, this may yield insight into the pattern of gene expression in the myelomonocytic progenitor compartment.
Translocation t(12;21)(p13;q22), associated with favorable prognosis, is one of the most frequent structural chromosomal aberrations found in pediatric B-lineage acute lymphoblastic leukemia (ALL). This aberration leads to the fusion of exon 5 of Tel gene with exons 2 or 3 of Aml1 gene and results in long and short transcripts of Tel-Aml1. The short variant is differed from long form by 39 base pairs, that reflects the loss of the exon 2 of Aml1 gene during rearrangement or in the process of alternative splicing. 1 It is known that various splice-variants/transcripts of fusion genes can be associated with different clinical features. For example, leukemic clone expressing Bcr-Abl p210 is more responsive to Gleevec therapy comparing with Bcr-Abl p190 positive cells. 2 There are data concerning differences in prognosis of patients with various transcripts of Pml-Rara, expressed in acute promyelocytic leukemia. 3 Biological or clinical significance of various Tel-Aml1 transcripts is still unknown. Therefore, we evaluated expression of Tel-Aml1 transcript variants and their relationship to laboratory features of childhood ALL.
A total of 172 patients with B-lineage ALL (age 0.8-18.0 years) were included into this study. Diagnosis of ALL was verified according to FAB-classification. Immunological diagnosis was defined using scoring system devised by the European Group for the Immunological Classification of Leukemia (EGIL). Cytogenetic study was conducted using standard G-banding on slides with cultured leukemic cells. Expression of Tel-Aml1 was evaluated using nested RT-PCR.
